News

Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
US clinical-stage biotech Vor Bio has announced the appointment of Dallan Murray as chief commercial officer, effective ...
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
Cambridge-based Sarepta Therapeutics Inc. stock dropped 1.6 percent in Monday trading. Capricor Therapeutics Inc. fell 13.8 percent and Replimune Group Inc. was down 5.7 percent. Prasad left the ...